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Abstract  
Safe and effective pharmacological treatments for severe obesity remain scarce. In this issue, 
Iepsen et al. show that obese patients with pathogenic melanocortin 4 receptor mutations, the 
most common form of monogenic obesity, lose weight with glucagon-like peptide 1 (GLP-1) 
receptor agonist therapy. 
 
Anthony P. Coll* 
MRC Metabolic Diseases Unit and Metabolic Research Laboratories, Wellcome Trust-MRC Institute 
of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital Cambridge CB2 0QQ  
*Correspondence to apc36@cam.ac.uk   
 
Main body  
Obesity, defined as an excessive storage of energy as fat, is a serious medical and socioeconomic 
problem. Any intervention, pharmacological or otherwise, aimed at tackling this problem is likely to 
be more effective when underpinned by a rational understanding of the processes at work that lead 
to the problem in the first place. The past 50 years have seen huge changes in how humans both 
consume and expend energy and, correctly, much effort is concentrated on reshaping our 
interactions with foodstuffs and our living and working environment. In addition, the last two 
decades have revealed a much deeper understanding of the biological processes that control our 
energy intake and expenditure. The central nervous system, in particular regions such as the 
hypothalamus, have a dominant role  in sensing and integrating  humoral and neuronal signals from 
the periphery and thence orchestrating  homeostatic effector systems.  Key to this has been the 
careful study of obese human subjects carrying single gene defects perturbing critical signalling 
pathways. Similarly, detailed characterisation of how peptide hormones derived from the 
enteroendocrine cells (EECs) of the gastrointestinal tract play an important role in appetitive and 
digestive biology has enabled an array of pharmacological interventions that target intrinsic 
pathways to enter the clinical arena. 
In this issue, Iepsen et al. (Iepsen et al., 2018) successfully link dysfunctional hypothalamic signalling 
with an established drug (liraglutide) derived from the gut hormone Glucagon-like peptide 1 ( GLP-1) 
to demonstrate an effective treatment for the most common form of monogenic obesity, 
melanocortin-4 receptor (MC4R) deficiency. 
GLP1 is a gut hormone derived from the preproglucagon precursor that has long been recognised to 
be a potent incretin hormone, augmenting glucose stimulated insulin secretion after a meal (Gribble 
and Reimann, 2017). GLP1 receptors are found in the pancreas, vagal afferent neurons and in brain 
nuclei including the hypothalamus and the brainstem. GLP1-R agonists such as liraglutide (where the 
addition of a fatty acid chain to the native GLP-1 molecule substantially increases its duration of 
action, Figure 1 B) are used widely in clinical practice to combat type 2 diabetes and obesity. 
MC4Rs sit at the heart of the central melanocortin pathway (Figure 1A). Specifically, within the 
arcuate nucleus of the hypothalamus 2 populations of neurons- one expressing  pro-
opiomelanocortin (POMC),  the other  agouti-related peptide (AgRP) - project to the paraventricular 
nucleus of the hypothalamus where they synapse with neurons expressing  the MC4R to regulate 
food intake (Cone, 2006). Peptide ligands called melanocortins derived from the larger POMC 
precursor act as anorectic agonist ligands at MC4R, while AgRP is antagonist and has an orexigenic 
effect. Loss of function MC4R mutations cause hyperhagia, early onset obesity and increased linear 
growth (Farooqi et al., 2003). 
The 14 individuals in this study all carried pathogenic mutations within MC4R, with a mean weight of 
122kg and a mean BMI of 37.5 kg/m2 .The intervention was a simple one: 3.0 mg of liraglutide given 
subcutaneously once daily for 16 weeks, and the effects were compared to those seen in a second 
group of similarly obese adults from the same clinic who did not carry MC4R mutations. This 
intervention caused identical results in both groups, with just over a 6 kg weight loss seen in all 
those treated. 
On the face of it then, perhaps not a surprising result. A drug proven to cause weight loss does just 
that when given to individuals with severe obesity. However, this may not have been wholly 
predictable. There are animal data to show that neuronal GLP1R mediates liraglutide’s anorectic 
effects (Sisley et al., 2014) and that around 10% of POMC neurons express Glp1r (Lam et al., 2017), 
so liraglutide weight loss effects could potentially be diminished if the melanocortin pathway were 
dysfunctional. 
The work by Iepsen and colleagues sets out clear “proof of concept” evidence that when one critical 
route is blocked, one should consider combatting the deficiency by trying to maximise signal 
transmission through another anorectic pathways. These data are also helpful in not feeding into 
despair that MC4R deficiency is somehow resistant to treatment and beyond intervention. Being a 
cell surface, G protein coupled receptor makes MC4R an attractive drug target, but initial studies 
with MC4R agonist therapies were stymied by unwanted effects, in particular issues with increased 
blood pressure (Greenfield et al., 2009). 
Other emerging pharmacological therapies hint to being more successful. When given setmelanotide 
(a synthetic 8 amino-acid, cyclic peptide MC4r agonist) for a month, a small cohort carrying 
heterozygous MC4R mutations lost around 3.5 kg without adverse cardiovascular effects (Collet et 
al., 2017). Setmelanotide has also proven efficacious in other subjects affected by monogenic 
obesity. Two individuals with POMC deficiency  had dramatic reduction in their hunger and 
substantial weight loss with this therapy (Kuhnen et al., 2016)  and , more recently, setmelanotide 
has been reported to bring about sustainable reduction in hyperphagia and body weight in obese 
individuals with leptin-receptor deficiency (Clement et al., 2018). 
Encouraging as all these studies are, there remain important questions around efficacy and safety in 
the longer term. For example, the weight loss with liraglutide in Iepsen et al’s study looked to be 
plateauing off at 16 weeks and by any measure the patients were still significantly obese. How might 
weight change if therapy were continued for several years? Would prolonged exposure, potentially 
at a higher dose, run the risk of more side effects? Might a cash strapped health economy be better 
investing resources into bariatric surgery than chronic GLP1-RA therapy? 
Prolonged setmelanotide therapy too needs close scrutiny. MC4R is part of a family of five closely 
related receptors and the melanocortin 1 receptor (MC1R) is a key signalling molecule on skin 
melanocytes  responsible for eumelanin synthesis.  In the POMC deficient patients (Kuhnen et al., 
2016), skin nevi that were present before drug administration darkened considerably following 
suggesting that setmelanotide and it will be crucial to determine over time if this is more than just a 
cosmetic issue. 
Nevertheless, this cluster of studies are welcomed reports and set the scene for longer and larger 
studies, both using single agents and combinatorial therapies, in patient groups significantly affected 
by severe obesity. Given the importance of the leptin-melanocortin pathway , dysfunction does  
pose  a substantial barrier to maintaining a healthy weight, but as our understanding of the multi-
layered complexity controlling  mammalian energy homeostasis becomes ever more comprehensive, 
we can look forward to additional ways to circumvent the roadblocks and bring about clinically 
meaningful outcomes for even more patients.  
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Figure1. A. The hypothalamus receives multiple inputs from the periphery to signal nutritional status. Within the 
arcuate nucleus of the hypothalamus  two opposing neuronal population (which have receptors for these 
peripheral signals)  produce peptides which act either as agonist anorexigenic ligands (a- and b- melanocyte 
stimulating hormone, MSH) or antagonist orexigenic ligand ( Agouti –related peptide, AgRP).
B. The Glucagon-like Peptide 1 receptor agonist Liraglutide is a modified version of endogenous GLP1, in which
lysine at position 34 is replaced with arginine, and  a palmitic acid chain is attached to lysine at position 26.
